Standard BioTools Inc. Restricted Cash, Current
Standard BioTools Inc. (LAB) had Restricted Cash, Current of $16.00 thousand as of 2022-06-30, per its 10-Q filed 2022-08-09.
Discontinued › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:RestrictedCashCurrent · last filed 2022-08-09
- 2022-06-30: Restricted Cash, Current $16.00K.
- 2022-03-31: Restricted Cash, Current $16.00K.
- 2021-12-31: Restricted Cash, Current $16.00K.
- 2021-09-30: Restricted Cash, Current $16.00K.
| Period end | Restricted Cash, Current |
|---|---|
| 2022-06-30 | $16.00K 10-Q · filed 2022-08-09 |
| 2022-03-31 | $16.00K 10-Q · filed 2022-05-09 |
| 2021-12-31 | $16.00K 10-Q · filed 2022-08-09 |
| 2021-09-30 | $16.00K 10-Q · filed 2021-11-09 |
| 2021-06-30 | $16.00K 10-Q · filed 2021-08-06 |
| 2021-03-31 | $16.00K 10-Q · filed 2021-05-07 |
| 2020-12-31 | $16.00K 10-Q · filed 2021-11-09 |
| 2020-09-30 | $15.00K 10-Q · filed 2020-11-09 |
| 2020-06-30 | $75.00K 10-Q · filed 2020-08-07 |
| 2020-03-31 | $75.00K 10-Q · filed 2020-05-11 |
| 2019-12-31 | $1.10M 10-K · filed 2020-02-27 |
| 2019-09-30 | $1.10M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $1.10M 10-Q · filed 2019-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |